Cardiovascular Systems Inc. (CSI) has acquired a line of peripheral support catheters from WavePoint Medical.
 
Peripheral support catheters are used in peripheral vascular intervention (PVI) procedures for guidewire support to enable lesion crossing, as well as for guidewire exchanges. Support catheters are used in approximately half of PVIs. When calcium is present, lesions can be challenging to cross with an interventional guidewire and often require advanced tools before vessel preparation and treatment. CSI intends to introduce the acquired catheters as its new ViperCross line in the first half of its fiscal year ending June 30, 2022.
 
WavePoint will also develop a portfolio of specialty catheters used to treat of chronic total occlusions (CTO) and complex percutaneous coronary intervention (PCI) procedures for CSI. CTOs represent a significant and growing segment of PCIs and often contribute to poor patient outcomes. Commercial availability is anticipated in CSI’s fiscal year ending June 30, 2023.
 
Scott R. Ward, Chairman, president, and CEO of CSI, told the press, “With the acquisition of these peripheral support catheters, CSI will soon offer a complete portfolio of products for the treatment of peripheral artery disease, including atherectomy, balloon catheters, guidewires, support catheters and embolic protection. In coronary, the successful development of a portfolio of CTO products will expand our existing offering of coronary support products. Together, these new products advance our ability to help physicians improve outcomes for patients undergoing complex peripheral and coronary interventions.”